Chatham Capital Group’s Bristol-Myers Squibb BMY Stock Holding History

Chatham Capital Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.24M	Hold	21,545	–	–	0.16%	124
2026 Q1	$1.31M	Hold	21,545	–	–	0.19%	114
2025 Q4	$1.16M	Hold	21,545	–	–	0.17%	124
2025 Q3	$972K	Sell	21,545 -250	-1%	-$11.7K	0.14%	131
2025 Q2	$1.01M	Hold	21,795	–	–	0.15%	127
2025 Q1	$1.33M	Hold	21,795	–	–	0.22%	109
2024 Q4	$1.23M	Buy	21,795 +200	+0.9%	+$11.2K	0.2%	110
2024 Q3	$1.12M	Hold	21,595	–	–	0.18%	116
2024 Q2	$897K	Hold	21,595	–	–	0.16%	128
2024 Q1	$1.17M	Sell	21,595 -500	-2%	-$25.5K	0.21%	109
2023 Q4	$1.13M	Sell	22,095 -93	-0.4%	-$4.88K	0.23%	110
2023 Q3	$1.29M	Hold	22,188	–	–	0.29%	97
2023 Q2	$1.42M	Hold	22,188	–	–	0.3%	97
2023 Q1	$1.54M	Hold	22,188	–	–	0.34%	96
2022 Q4	$1.6M	Sell	22,188 -550	-2%	-$41.5K	0.37%	87
2022 Q3	$1.62M	Hold	22,738	–	–	0.4%	81
2022 Q2	$1.75M	Buy	22,738 +93	+0.4%	+$7.08K	0.4%	77
2022 Q1	$1.65M	Hold	22,645	–	–	0.32%	86
2021 Q4	$1.41M	Sell	22,645 -2,520	-10%	-$148K	0.25%	95
2021 Q3	$1.49M	Hold	25,165	–	–	0.29%	86
2021 Q2	$1.68M	Hold	25,165	–	–	0.33%	81
2021 Q1	$1.59M	Buy	25,165 +14,250	+131%	+$887K	0.33%	81
2020 Q4	$677K	Buy	10,915 +450	+4%	+$27.7K	0.15%	123
2020 Q3	$631K	Buy	10,465 +1,000	+11%	+$60.2K	0.16%	113
2020 Q2	$557K	Buy	9,465 +520	+6%	+$31.1K	0.14%	116
2020 Q1	$499K	Hold	8,945	–	–	0.15%	117
2019 Q4	$574K	Hold	8,945	–	–	0.14%	118
2019 Q3	$454K	Hold	8,945	–	–	0.12%	123
2019 Q2	$406K	Hold	8,945	–	–	0.1%	132
2019 Q1	$427K	Sell	8,945 -100	-1%	-$4.98K	0.11%	127
2018 Q4	$470K	Hold	9,045	–	–	0.13%	116
2018 Q3	$562K	Hold	9,045	–	–	0.14%	107
2018 Q2	$501K	Hold	9,045	–	–	0.13%	109
2018 Q1	$572K	Hold	9,045	–	–	0.15%	101
2017 Q4	$554K	Buy	9,045 +1,600	+21%	+$100K	0.15%	101
2017 Q3	$475K	Hold	7,445	–	–	0.13%	107
2017 Q2	$415K	Sell	7,445 -116	-2%	-$6.31K	0.11%	117
2017 Q1	$411K	Sell	7,561 -86	-1%	-$4.72K	0.11%	115
2016 Q4	$447K	Sell	7,647 -84	-1%	-$4.59K	0.13%	108
2016 Q3	$417K	Sell	7,731 -139	-2%	-$8.93K	0.13%	110
2016 Q2	$579K	Buy	7,870 +500	+7%	+$35.3K	0.18%	93
2016 Q1	$471K	Buy	7,370 +1,000	+16%	+$63.1K	0.15%	99
2015 Q4	$438K	Sell	6,370 -20,000	-76%	-$1.32M	0.14%	102
2015 Q3	$1.56M	Sell	26,370 -2,675	-9%	-$170K	0.53%	43
2015 Q2	$1.93M	Buy	29,045 +19,818	+215%	+$1.31M	0.54%	46
2015 Q1	$595K	Hold	9,227	–	–	0.17%	106
2014 Q4	$545K	Sell	9,227 -30	-0.3%	-$1.69K	0.16%	110
2014 Q3	$474K	Buy	9,257 +4,112	+80%	+$205K	0.15%	111
2014 Q2	$250K	Hold	5,145	–	–	0.1%	98
2014 Q1	$267K	Sell	5,145 -500	-9%	-$26.6K	0.11%	94
2013 Q4	$300K	Hold	5,645	–	–	0.12%	97
2013 Q3	$261K	Sell	5,645 -1,200	-18%	-$52.7K	0.12%	96
2013 Q2	$306K	Buy	+6,845	New	+$297K	0.15%	95

Other funds holding BMY

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

ORIO

Old Republic International (ORI) Chicago, Illinois $2.67B AUM 26.94% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

UBP

Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

Chatham Capital Group's BMY Position: Q2 2026 in Review

Chatham Capital Group held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 21,545 shares worth $1.24M. The position accounts for 0.16% of the portfolio, ranked #124.

Chatham Capital Group first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.93M in Q2 2015. 440 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Chatham Capital Group held 21,545 shares of Bristol-Myers Squibb worth $1.24M as of Q2 2026.
Chatham Capital Group left its Bristol-Myers Squibb share count unchanged in Q2 2026.
Bristol-Myers Squibb made up 0.16% of Chatham Capital Group's portfolio in Q2 2026, its #124 holding.
Chatham Capital Group first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
Chatham Capital Group's Bristol-Myers Squibb position peaked at $1.93M in Q2 2015.
440 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Chatham Capital Group's 13F filing for Q2 2026, filed 13 Jul 2026.